GSK’s shingles shot cuts cardiovascular risk compared with Merck’s Zostavax

Data ReadoutpositiveGSK shingles shotZostavaxPositive

AI Analysis

Summary

GSK's shingles vaccine demonstrates superior cardiovascular safety profile compared to Merck's Zostavax, with reduced cardiovascular risk in comparative analysis.

Outcome Details

GSK's shingles vaccine demonstrated reduced cardiovascular risk compared to Merck's Zostavax

Importance:6/10

Sentiment:

0.70

vaccinesshinglescardiovascularcomparative efficacy

Related Companies

$GSK

Read the original article

Published by Seeking Alpha Healthcare on August 26, 2026 6:11 PM

Read Original